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Summary 
Nitric oxide (NO) is synthesized in skeletal muscle by 
neuronal-type NO synthase (nNOS), which is localized 
to sarcolemma of fast-twitch fibers. Synthesis of NO 
in active muscle opposes contractile force. We show 
that nNOS partitions with skeletal muscle membranes 
owing to association of nNOS with dystrophin, the pro- 
tein mutated in Duchenne muscular dystrophy (DMD). 
The dystrophin complex interacts with an N-terminal 
domain of nNOS that contains a GLGF motif, mdx mice 
and humans with DMD evince a selective loss of nNOS 
protein and catalytic activity from muscle membranes, 
demonstrating a novel role for dystrophin in localizing 
a signaling enzyme to the myocyte sarcolemma. Aber- 
rant regulation of nNOS may contribute to preferential 
degeneration of fast-twitch muscle fibers in DMD. 
Introduction 
Nitric oxide (NO) is a major endogenous mediator involved 
in diverse developmental and physiological processes (for 
reviews see Bredt and Snyder, 1994a; Marietta, 1993; 
Moncada and Higgs, 1993; Nathan and Xie, 1994). Be- 
cause NO is a short-lived free radical, regulation of signal- 
ing occurs largely at the level of NO biosynthesis. Three 
mammalian NO synthase (NOS) genes have been identi- 
fied, and each forms NO from the guanidine nitrogen of 
L-arginine in a unique cytochrome P-450-type reaction that 
consumes reduced nicotinamide adenine dinucleotide 
phosphate (NADPH). Endothelial and neuronal NOS en- 
zymes (eNOS and nNOS, or types I and III, respectively) 
are discretely expressed in specific tissues and rapidly 
transduce signaling events in a calcium-dependent man- 
ner. eNOS activity accounts for endothelium-dependent 
blood vessel relaxation, while nNOS occurs discretely in 
a variety of cell types, including neurons, epithelial cells, 
mesangial cells, and skeletal muscle cells. Physiological 
actions for nNOS have been best characterized in the pe- 
ripheral nervous system, where NO functions as a nonad- 
renergic-noncholinergic transmitter in numerous path- 
ways, including the gastrointestinal and urogenital tracts. 
In contrast with these calcium-dependent enzymes, a 
largely inducible calcium-independent NOS (iNOS, or type 
II) is expressed at highest levels in immunologically acti- 
vated cells. NO formed in this pathway functions in a non- 
specific immune response that mediates certain cytotoxic 
and bacteriocidal actions of activated macrophages (Hibbs 
et al., 1987). 
In addition to controlling diverse cellular processes, NO 
also participates in certain pathophysiological conditions. 
Deregulation of nNOS in brain is associated with gluta- 
mate receptor overactivity and contributes to neuronal 
damage in animal models of stroke (Dawson et al., 1992). 
Mutant mice lacking nNOS are relatively resistant to neu- 
ronal damage following focal cerebral ischemia (Huang 
et al., 1994). iNOS activity contributes to cellular damage 
in a variety of immunological disorders such as rheumatoid 
arthritis and septic shock. 
Maintenance of physiological NO signaling in the face 
of this potential toxicity requires tight regulation of NOS 
at numerous points. In addition to transcriptional control, 
NOS proteins are all regulated by calmodulin (Bredt and 
Snyder, 1990; Cho et al., 1992a), which links NO formation 
to increases in cellular calcium. A more complex level of 
regulation is reflected by targeting of NOS proteins to intra- 
cellular membranes. This subcellular targeting restricts 
NO signaling to specific targets within a limited microenvi- 
ronment while minimizing aberrant toxic pathways. Mem- 
brane association of eNOS is mediated by two fatty acid 
modifications (Robinson et al., 1995). Cotranslational N-ter- 
minal myristoylation of eNOS is necessary for membrane 
association. In addition, eNOS is posttranslationally palmi- 
toylated by a dynamic process regulated by a specific ago- 
nist, bradykinin, nNOS, which lacks consensus sequences 
for fatty acid modification, also occurs largely in particulate 
fractions (Hecker et al., 1994). The majority of nNOS im- 
munoreactivity in neurons is associated with rough endo- 
plasmic reticulum and specialized electron-dense synap- 
tic membrane structures, while in skeletal muscle, nNOS 
is associated with the sarcolemma (Kobzik et al., 1994). 
Understanding mechanisms for targeting of nNOS 
within cells will help identify pathways associated with NO 
signaling and clarify how disruption of this transduction 
machinery contributes to disease processes. ]-he regular 
and defined structure of skeletal muscle makes it an ideal 
tissue in which to address these questions. Furthermore, 
recent studies have identified a major role for NO in skele- 
tal muscle, nNOS is expressed at higher levels in human 
skeletal muscle than in human brain (Nakane et al., 1993). 
In mature skeletal muscle, nNOS is enriched in fast-twitch 
muscle fibers, where NO opposes contractile ferce (Kobzik 
et al., 1994). Additionally, NO produced by cultured myo- 
cytes facilitates myoblast fusion (Lee et al., 1994) and me- 
diates activity-dependent synaptic suppression in myo- 
cyte neuronal cocultures (Wang et al., 1995). 
These physiological actions of NO in muscle are facili- 
tated by restriction of nNOS protein to the sarcolemmal 
membrane (Kobzik et al., 1994). The sarcolernma of skel- 
etal muscle is a complex structure reinforced by an 
actin-containing cytoskeleton. In addition to ubiquitous 
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structural elements such as spectrin, skeletal muscle sar- 
colemma contains a unique network formed around dys- 
trophin and related proteins (Ervasti and Campbell, 1993). 
Dystrophin was originally identified by positional cloning 
as the gene product mutated in Duchenne muscular dys- 
trophy (DMD) (Monaco et al., 1986). Subsequent studies 
have identified a family of intracellular and transmem- 
brane glycoproteins in a dystrophin-associated complex 
that links the extracellular matrix with the actin-based cy- 
toskeleton. Recent studies indicate a major role for this 
complex in neuromuscular development and disease. 
c~-Dystroglycan, an extracellular glycoprotein linked to 
dystrophin, serves as a physiologic receptor for agrin, 
which mediates clustering of acetylcholine receptors 
(Campanelli et al., 1994; Gee et al., 1994). On the other 
hand, disruption of dystrophin or other proteins in this com- 
plex results in muscular dystrophy in both humans and 
animals (Campbell, 1995). Despite these data, it not 
known how the dystrophin complex mediates signal trans- 
duction, nor is it clear why disruption leads to muscle dis- 
ease. Indeed, none of the previously identified dystrophin- 
associated proteins have known catalytic activities. 
In this report we demonstrate that sarcolemmal nNOS 
is complexed with dystrophin in skeletal muscle. The dys- 
trophin complex interacts with the N-terminus of nNOS, 
which contains a motif of previously unknown function 
present in a family of cytoskeletal-associated proteins in- 
cluding syntrophins, known binding partners of dystro- 
phin. In human DMD and mdx mice, which lack dystrophin, 
nNOS is absent from the sarcolemma and accumulates 
in the cytosol. This derangement of nNOS is specific for 
dystrophin abnormalities, as nNOS disposition is unaf- 
fected in other muscular diseases. These observations 
provide molecular evidence for a specific intracellular sig- 
naling molecule linked to the dystrophin-associated com- 
plex and suggest roles for NO in processes of neuro- 
muscular development and disease associated with this 
complex. 
Results 
nNOS but Not eNOS Is Present in Cytoskeletal 
Extracts from Skeletal Muscle 
Previous work indicates that the majority of nNOS in hu- 
man and rat skeletal muscle occurs in membrane fractions 
(Nakane et al., 1993). We similarly find that -80% of the 
total nNOS protein in mouse skeletal muscle associates 
with the particulate fractions (data not shown). To under- 
stand mechanisms for membrane association of nNOS, 
we characterized the extractability of nNOS from mouse 
quadriceps and found that nNOS is anchored both to mi- 
crosomal membranes and to cytoskeleton (Figure 1A). 
Thus, the majority of nNOS protein remained membrane 
associated following extensive washing of skeletal muscle 
heavy microsomes (Mitchell etal., 1983) with 0.5 M NaCI. 
Solubilization of washed membranes with 0.5% Triton 
X-100 released about half of this particulate nNOS, with 
the remainder in an insoluble cytoskeletal pellet (Figure 
1A). By contrast, eNOS, which is membrane associated 
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Figure 1. Differential Extractability of nNOS and eNOS in Skeletal 
Muscle Homogenates 
(A) Western blotting indicates that significant nNOS remains in an 
insoluble pellet (P) following sequential extraction of mouse quadricep 
homogenates with 100 mM NaCI (SO, 500 mM NaCI ($2), and 0.5% 
Triton X-100 ($3). nNOS is present in each of these fractions. 
(B) eNOS occurs only in membrane-associated fractions. Probing the 
same blot with an eNOS monoclonal antibody indicates that eNOS is 
completely extracted by 500 mM NaCI ($2) and 0.5% Triton X-100 ($3). 
eNOS is absent from cytosol ($1) and the insoluble pellet (P). After 
subcellular fractionation and 7.5% SDS-PAGE (100 ~g protein per 
lane), nNOS and eNOS were sequentially detected by protein immu- 
noblot. Positions of molecular size markers are indicated in kilodaltons. 
owing to N-terminal myristoylation, was quantitatively sol- 
ubilized from these same preparations by Triton X-100 
(Figure 1B). 
This differential fractionation suggested that unique de- 
terminants in nNOS anchor this isoform to the skeletal 
muscle cytoskeleton. The amino acid sequence of nNOS 
contains a 230 amino acid N-terminal domain that is not 
present in eNOS (Figure 2A). Beyond this extended N-ter- 
minus of nNOS, the two proteins share >60% sequence 
identity. Similar enzymatic activities of eNOS and nNOS 
suggest that the unique N-terminus of nNOS may not be 
required for catalytic activity. To analyze the role of the 
extended N-terminal region of nNOS, we constructed a 
deletion mutant, nNOSA 1-226, lacking the first 226 amino 
acids. Expression vectors containing full-length nNOS and 
nNOSA1-226 were transiently transfected into COS cells. 
NOS catalytic activity was measured in tissue homoge- 
nates 3 days following transfection. Kinetic characteristics 
of NOS activity for the nNOSA1-226 mutant was es- 
sentially indistinguishable from the full-length isoform. 
Both constructs displayed similar Vr~ and Km for arginine 
as well as regulation by calcium/calmodulin (Figures 2C 
and 2D). 
Rather than regulating catalytic activity, we reasoned 
that the N-terminal domain of nNOS may instead target 
nNOS to skeletal muscle sarcolemma. Within this domain, 
nNOS contains a 66 amino acid motif that bears homology 
to a heterogeneous family of signaling enzymes that share 
the property of being localized to specialized cell-cell junc- 
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Figure 2. The Extended N-Terminus of nNOS 
Contains a GLGF Domain That Is Not Required 
for Enzyme Activity 
(A) Schematic alignment of cofactor-binding 
domains of eNOS and nNOS, indicating N-ter- 
minal myristoylation (Myr) of eNOS and ex- 
tended N-terminus of nNOS. The jagged line 
indicates the region deleted for the nNOSA1- 
226 mutant. Abbreviations ot defined in text: 
CaM, calmodulin; FMN, flavin mononucleo- 
tide; FAD, flavin adenine dinucleotide. 
(B) Alignment of the GLGF domain of nNOS 
with syntrophins and a family of other cytoskel- 
etal-associated proteins. Abbreviations ofpro- 
teins not defined in text: T-SYN and SYN-1, 
syntrophins; DLG, dig-l; DSH, disheveled; 
PTP, protein-tyrosine phosphatase. 
(C and D) COS cells were transfected with 10 
~g of expression vector using a cytomegalovi- 
rus promoter to drive expression of either full- 
length nNOS (C) or the truncation mutant 
nNOSA1-226 (D). NOS activity was measured 
in cell homogenates 3 days following transfec- 
tion in the presence of either 200 ~tM free cal- 
cium (closed squares) or 2 mM EDTA (closed 
circles). Kinetic constants (Vma, and Kin) were 
calculated by Scatchard plot analysis. Data are 
means of triplicate determinations that varied 
by <10%. This experiment was replicated twice 
with similar esults. 
tions (Figure 2B). Proteins containing this motif, which is 
named GLGF.for a conserved tetrapeptide (Cho et al., 
1992b), include dig-l, the product of the lethaldiscs large 
tumor suppressor gene that localizes to the undercoat of 
the septate junction in Drosophila (Bryant and Woods, 
1992); disheveled, a gene required for planar cell polarity 
in Drosophila; PSD-95, a brain-specific protein that local- 
izes to the postsynaptic density in mammals (Cho et al., 
1992b); ZO-1, a peripheral membrane protein that local- 
izes to tight junctions (zona occludens) of epithelial and 
endothelial cells (Willott et al., 1993); and certain protein- 
tyrosine phosphatases uch as PTP1E, which are thought 
to localize at the junction between the plasma membrane 
and the cytoskeleton. Interestingly, we and others (Ponting 
and Phillips, 1995) noted homology to syntrophins, a fam- 
ily of recently cloned dystrophin-binding proteins, which 
colocalize with NOS beneath the sarcolemmal membrane 
of skeletal muscle (Adams et al., 1993; Ahn et al., 1994). 
In fact, syntrophins are more closely related to NOS in 
this domain than any other known gene (Figure 2B), sug- 
gesting a possible role for dystrophin in regulating the sar- 
colemmal ocalization of nNOS. 
Association of nNOS and Dystrophin in Skeletal 
Muscle Extracts 
We evaluated possible association of nNOS with dys- 
trophin by means of succinylated wheat germ agglutinin 
(sWGA)-Sepharose affinity chromatography, nNOS, which 
lacks glycosylation sites, is not expected to adhere to a 
wheat germ column, while dystrophin, which is bound to 
a glycoprotein complex, is routinely purified by this tech- 
nique (Ervasti et al., 1991). To ensure specificity of this 
association, we conducted parallel experiments with mdx 
mice that specifically lack dystrophin owing to a nonsense 
mutation (Sicinski et al., 1989), but that express nNOS at 
near-normal evels. Quadriceps from wild-type and mdx 
mice were homogenized and solubilized in buffer con- 
taining 0.2 M NaCI and 1% digitonin. Solubilized homoge- 
nates were applied to sWGA-Sepharose columns that 
were extensively washed with buffer contaiining 0.5 M 
NaCI and 0.5% Triton X-100. Tightly bound proteins were 
affinity eluted with 0.3 M N-acetyI-D-glucosarnine (NAG). 
Western blot analysis reveals presence of nNOS in NAG 
eluates from wild-type but not mdx tissue (Figure 3A). 
We also conducted analogous experiments and evalu- 
ated association of dystrophin with nNOS using a 2',5'- 
ADP-agarose column, which tightly binds nNOS at its 
C-terminal NADPH-binding motif (Bredt and Snyder, 1990). 
Dystrophin has no nucleotide-binding site (Koenig et al., 
1988) and would not be expected to adhere to, a 2',5'-ADP 
column. To ensure specificity of a potential nNOS-dys- 
trophin interaction, we conducted parallel purifications 
from skeletal muscle of nNOS knockout mice, which are 
devoid of nNOS protein (Huang et al., 1993) yet express 
dystrophin at normal levels. Salt-washed heavy micro- 
somes from wild-type and nNOS knockout mouse quadri- 
ceps were solubilized in 1% digitonin and allowed to ad- 
here to 2',5'-ADP-agarose columns. The columns were 
extensively washed with buffers containing 0.5 M NaCI 
and 0.5% Triton X-100. Tightly bound proteins were eluted 
with buffer containing 20 mM NADPH. Western blot anal- 
ysis revealed presence of dystrophin in NADPH eluate 
fractions from wild-type but not nNOS knockout tissue 
(Figure 3B). 
To evaluate directly binding of dystrophin-associated 
complexes to the N-terminal domain of nNOS, we coupled 
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Figure 3. Association of nNOS and Dystrophin in Skeletal Muscle 
(A and B) Dystrophin-associated glycoprotein complex and nNOS were 
purified by sWGA and 2',5'-ADP-agarose chromatography, respec- 
tively, from wild-type (WT), mdx, and NOS knockout (NOS ~ ) skeletal 
muscle. For (A)-(C), protein homogenates (200 p.g per lane) and ali- 
quots of affinity eluates (150 p.I per lane) were resolved on 7.5% 
(c~-nNOS) or 6% (a-dystrophin) SDS gels and transferred to PVDF 
membranes, and immunoreactive bands were visualized by ECL. 
(A) Western blotting indicates that total nNOS levels in crude extracts 
are similar in wild-type (WT) and m x muscle, nNOS coelutes with 
dystrophin on an sWGA affinity column in muscle homogenates from 
wild-type mouse, nNOS does not adhere to an sWGA column in ex- 
tracts from mdx mouse. 
(B) Western blotting for dystrophin reveals that dystrophin levels are 
equivalent in crude samples from wild-type (WT) and nNOS knockout 
(NOS +) skeletal muscle. Dystroph in coelutes with NOS on a 2',5'-ADP 
affinity column in muscle homogenates from wild-type but not nNOS 
knockout mouse. 
(C) Glutathione-Sepharose beads bound to GST or GST-nNOS(1- 
299) were incubated with solubilized skeletal muscle membranes. 
After extensive washing, the beads were eluted with 0.2% SDS and 
proteins were separated by SDS-PAGE, and retention of dystrophin 
protein was analyzed by Western blotting. 
(D) Western blotting for nNOS from equally loaded (5 p.g per lane) 
fractions from sWGA chromatography shows large enrichment of 
nNOS in NAG eluate fractions. Abbreviations: L, load; F, flowthrough; 
Wl, 500 mM NaCI wash; W2, 500 mM NaCI and 0.5% Triton X-100 
wash; E, 0.3 M NAG eluate. 
(E) Reloading samples from sWGA column with 6-fold higher protein 
in load (L) and flowthrough (F) (21 p.g per lane) than in wash (W1 and 
W2) and eluate (E) fractions (3.5 Ixg per lane) shows purification f 
nNOS and dystrophin, but not eNOS, by sWGA. 
(F) Immunoprecipitation from NAG eluate fractions indicates that a 
monoclonal antibody to dystrophin (12 M) potently precipitates nNOS 
(lane 1). Control experiments containing a monoclonal anti-Myc anti- 
body (12 nM) or lacking any primary antibody (lanes 2 and 3) fail to 
precipitate nNOS. 
a protein containing glutathione S-transferase (GST) fused 
to the first 299 amino acids of nNOS to glutathione beads. 
The GST-nNOS(1-299) beads and control GST beads 
were incubated with solubilized homogenates of mouse 
skeletal muscle. After extensive washing of the beads, 
bound proteins were eluted with sample buffer. Western 
blotting indicated that GST-nNOS(1-299) beads but not 
control beads retained dystrophin protein (Figure 3C). 
Other proteins evaluated, such as myosin, were retained 
in very small but equivalent amounts by both GST and 
GST-nNOS(1-299) beads (data not shown), indicating 
specificity of the association with dystrophin. 
To quantitate nrichment of nNOS by sWGA chromatog- 
raphy, we conducted larger scale purifications from rat 
skeletal muscle tissue. Western blot analysis for nNOS 
in equally loaded fractions (5 tag per lane) from sWGA 
chromatography revealed a striking enrichment of nNOS 
in the NAG eluate (Figure 3D). nNOS was typically purified 
60-fold by sWGA chromatography; thus, equal nNOS 
immunoreactivity was detected in 30 tag of loaded fractions 
and 500 ng of NAG eluate fractions (data not shown). To 
evaluate the retention of nNOS by sWGA, we reloaded 
fractions from sWGA chromatography onto SDS gels with 
6-fold more total protein in load and flowthrough lanes (21 
~tg) than in wash and eluate lanes (3.5 ~g) (Figure 3E). 
Clearly, the majority of particulate nNOS adhered to the 
sWGA column as minimal nNOS is present in the 
flowthrough. We probed the blot shown in Figure 3E with 
antisera to dystrophin and found that essentially all the 
solubilized dystrophin adhered to the sWGA column and 
that dystrophin was enriched to a somewhat greater de- 
gree than nNOS by this procedure ( -150- fo ld  purifica- 
tion). The somewhat higher recovery of dystrophin ap- 
pears to be due to slow dissociation of nNOS from the 
sWGA column (dystrophin complex) under stringent con- 
ditions, as evidenced by some "bleeding" of nNOS with 
the 500 mM NaCI and 0.5% Triton X-100 wash steps (Fig- 
ure 3E). We also probed this same blot with an antibody to 
eNOS, which is similar to nNOS but lacks a GLGF domain. 
eNOS did not specifically adhere to the sWGA column, 
and only residual amounts of eNOS were found in NAG 
eluate fractions. 
To determine whether nNOS associates with dystrophin 
complexes eluting from sWGA, we conducted immunopre- 
cipitation experiments. NAG eluate samples were incu- 
bated for 1 hr with a monoclonal antibody to c~-dystrophin, 
and imrnunocomplexes were pelleted with anti-mouse im- 
munoglobulin G (IgG) linked to protein A-Sepharose. 
Western blot analysis revealed potent immunoprecipita- 
tion of nNOS with 2.0 i~g/ml (12 nM) c~-dystrophin. Control 
immunoprecipitations lacking the primary dystrophin anti- 
body or containing an alternate monoclonal (anti-Myc, 12 
nM; BABCO) did not precipitate detectable nNOS, demon- 
strating specificity of the interaction (Figure 3F). 
nNOS Is Displaced from Sarcolemma and 
Accumulates in Cytosol of mdx Skeletal Muscle 
The absence of dystrophin leads to a dramatic reduction 
of other dystrophin-associated proteins, including eL- and 
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Figure 4. nNOS Is Displaced from Particulate Fractions of mdx Skele- 
tal Muscle 
(A) Subcellular fractions (S,, S=, $3, and P) of mouse quadriceps from 
wild-type (WT) and mdx mice (age matched at 7-8 weeks) were pre- 
pared as described in Figure 1. Western blotting shows that nNOS in 
skeletal muscle of mdx mice is largely extracted from membranes with 
100 mM NaCI (S~) and is completely removed with 500 mM NaCI ($2). 
In wild-type mice, the majority of nNOS remains membrane associated 
following the 500 mM NaCI wash. Of this remaining nNOS, approxi- 
mately half is removed by a 0.5% Triton X-100 extraction ($3) and half 
is present in an insoluble pellet (P). 
(B) Dystrophin is enriched in detergent extract ($3) and cytoskeletal 
pellet (P) fractions in wild-type mice (WT) and is absent from mdx 
muscle. 
13-dystroglycan and syntrophins, in the sarcolemma of mdx 
mice (Ohlendieck and Campbell ,  1991) and in patients 
with DMD (Ervasti et al., 1990). We therefore evaluated 
the distribution of nNOS in mdx mice. Overall nNOS levels 
and enzyme activity were modestly decreased ( -  80% of 
control levels) in skeletal muscle from mdx mice (data not 
shown). Subcellular analysis revealed that nNOS distrib- 
uted with dystrophin in membrane-associated and cy- 
toskeletal fractions from wild-type skeletal muscle (Fig- 
ures 4A and 4B). However, in preparations from mdx 
mouse, nNOS was quantitatively solubil ized from micro- 
somal membranes washed with 0.5 M NaCI; no nNOS 
protein was detected in detergent extract or cytoskeletal 
fractions (Figure 4A). 
NOS catalytic activity was also absent from particulate 
fractions of mdx skeletal muscle. As previously reported 
in rat (Kobzik et al., 1994), NOS activity was enriched in 
the particulate fraction of mouse skeletal muscle homoge- 
nates (Table 1). NOS activity in the soluble fraction of mdx 
skeletal muscle occurred at levels 75% greater than wild 
type, but NOS activity was not detectable in the particulate 
fraction from mdx muscle. In brain, NOS-specific activity 
was nearly equivalent in soluble and particulate fractions. 
This distribution was unchanged in mdx brain, suggesting 
that proteins other than dystrophin anchor nNOS to neu- 
ronal membranes. 
Immunohistochemical studies further identified an ab- 
sence of sarcolemmal nNOS in mdx skeletal muscle. Us- 
ing a polyclonal antiserum, we found that nNOS immuno- 
f luorescence was restricted to the sarcolemma of a subset 
of skeletal muscle fibers (Figure 5), which were previously 
noted to be fast twitch (Kobzik et al., 1994). However,  
nNOS immunoreactivity was absent from the sarcolemma 
of mdx muscle (Figure 5). To determine whether this de- 
rangement of nNOS was specific for dystrophin abnormali- 
ties, we evaluated the distribution of nNOS in dy mice, 
which have severe muscular dystrophy due to absence of 
an extracellular matrix protein, merosin, but have a normal 
distribution of dystrophin at the sarcolemma (Sunada et 
al., 1994). We found that nNOS is present normally at the 
sarcolemma of dy dystrophic mice (Figure 5). 
Table 1. NOS Activity in Extracts from Wild-Type and m x Mouse 
Tissues 
NOS Activity Wild Type a mdx ~ 
Skeletal muscle 
Soluble fraction 33.3 58.3 
Particulate fraction 252 <0.5 
Brain 
Soluble fraction 1020 1060 
Particulate fraction 1080 1210 
Particulate and soluble fractions of quadriceps skeletal muscle from 
wild-type and mdx mice were prepared and assayed for NOS activity 
as described in Experimental Procedures. Data are means of triplicate 
determinations that varied by <10%. This experiment was repeated 
three times with similar results. 
In counts per minute per milligram of protein. 
Figure 5. nNOS Is SelectivelyAbsent from SarcolemmaofmdxSkele- 
tal Muscle 
Immunofluorescent s aining for nNOS in quadriceps of wffd-type, mdx, 
dy, and nNOS knockout mouse was performed using an affinity- 
purified polyclonal antibody. Cryostat muscle sections from wild-type, 
mdx, dy, and nNOS knockout mouse were stained under identical 
conditions using an affinity-purified nNOS antiserum and  FITC- 
linked secondary antibody. 
(A and B) nNOS immunostaining is present at he surface membranes 
of skeletal muscle fibers from wild-type (WT) mouse (A), but is absent 
from mclx mouse (B) skeletal muscle sarcolemma. 
(C) Homozygous dystrophic dy mice display normal sarcolemmal 
nNOS labeling of intact fibers. 
(D) Skeletal muscle from NOS knockout (NOS ~ ) mouse is entirely 
devoid of immunostaining. 
Magnification, 188x. 
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Figure 6. nNOS Is Absent from Sarcolemma of DMD Muscle Fibers 
(A) Skeletal muscle cryosections of normal (N1) or DMD (D1) skeletal muscle were immunostained with antibodies to dystrophin, nNOS, and 
spectrin. 
(B) Representative muscle sections from two additional normal patients (N2 and N3) and two DMD cases (D2 and D3) were labeled with antibodies 
to dystrophin and nNOS. 
(C) Control experiments using two independently generated nNOS antisera showed similar staining of human tissues. No immunofluorescence 
was detected in the absence of primary (1°) antibody. 
Magnification, 122 x. 
We conducted several control experiments to ensure 
for specificity of the immunofluorescence. No specific la- 
beling was present in muscle tissues incubated with preim- 
mune serum or without primary antiserum (data not shown). 
Most importantly, labeling was not present in transgenic 
mice containing a targeted mutation (Huang et al., 1993) 
of  the nNOS gene (Figure 5). 
nNOS Is Absent from Skeletal Muscle Sarcolemma 
in DMD 
In addition to animal models, we evaluated the localization 
of nNOS in human muscle tissues. A total of 20 human 
tissues were evaluated, including 13 normal specimens 
and seven from patients with DMD. Skeletal muscle cross 
sections were processed for immunofluorescence for 
nNOS, dystrophin, and spectrin. All normal specimens 
showed colocalization of nNOS, dystrophin, and spectrin 
beneath the sarcolemma of muscle fibers (Figures 6A and 
6B), indicating that nNOS shares a similar distribution in 
both human and rodent skeletal muscle. In all seven biop- 
sies from patients with DMD, the disruption of dystrophin 
resulted in absence of nNOS staining of sarcolemma (Fig- 
ures 6A and 6B). Normal sarcolemmal labeling for spectrin 
confirmed that this structural cytoskeleton was not dis- 
rupted in the DMD tissues (Figure 6A). Two independently 
raised nNOS antibodies (see Experimental Procedures) 
yielded similar immunofluorescent s aining patterns, and 
no specific labeling was found in muscle sections incu- 
bated without primary antibody (Figure 6C). 
Absence of dystrophin in DMD results in disruption of 
the dystrophin-associated glycoprotein complex and a 
dramatic reduction in overall levels of certain dystrophin- 
associated proteins in muscle. To evaluate total nNOS 
levels in skeletal muscle tissues from human DMD, we 
conducted Western blot analysis. Strikingly, we found that 
nNOS levels are dramatically reduced in human dystro- 
phic muscle (Figure 7A). Densitometric scanning of nNOS 
immunoreactive bands in equally loaded Western blots 
revealed - 75% decrease of nNOS in DMD tissues. West- 
ern blots were also probed with an antibody to dystrophin 
that was essentially absent from all cases of DMD exam- 
ined (Figure 7B). Immunoblotting for spectrin confirmed 
that similar amounts of protein were loaded in all cases 
and that the structural cytoskeleton was intact (Figure 7C). 
Discussion 
This study defines a role for the dystrophin complex in 
tethering nNOS to skeletal muscle sarcolemma, nNOS 
was originally characterized from brain cytosol that facili- 
tated biochemical isolation of the enzyme (Bredt and Sny- 
der, 1990). Subsequent studies indicate that the majority 
of nNOS activity and immunoreactivity are present in the 
particulate fraction of tissue extracts (Hecker et al., 1994; 
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Figure 7. nNOS Levels Are Diminished in DMD Skeletal Muscle 
Skeletal muscle tissue homogenates from three cases of DMD and 
three normal muscle biopsies were resolved by SDS-PAGE, 
(A) Immunoblot analysis confirms that dystrophin isessentially absent 
from DMD muscle. 
(B) nNOS levels are significantly decreased in all three cases of DMD. 
(C) Spectrin levels are nearly equal in ormal and DMD biopsies. 
Kobzik et al., 1994). Thus, >60% of NOS activity is associ- 
ated with the particulate fraction of cortical extracts 
(Hecker et al., 1994), and >85% of NOS immunoreactivity 
in monkey visual cortex is identified as axonal or dendritic 
profiles (Aoki et al., 1993). Membrane association of eNOS 
is mediated by fatty acid modifications; however, particu- 
late nNOS in skeletal muscle and brain (J. E. B. and 
D. S. B., unpublished data) is not solubilized by detergent 
extraction, implying association of nNOS with the cytoskel- 
eton. Our finding that nNOS remains membrane associ- 
ated in brain of mdx mice implies that distinct nNOS an- 
choring complexes likely exist in other tissues. Possible 
candidates in brain include complexes formed about dys- 
trophin-related proteins, utrophin (Matsumura et al., 
1992), and the 87 kDa postsynaptic protein identified from 
Torpedo electric organ (Wagner et al., 1993), as well as 
homologs of protein 4.1, such as NF-2, which have been 
shown to bind GLGF domains in vitro (Marfatia et al., 
1994). 
The GLGF domain is a recently identified protein motif 
that is present in a heterogeneous family of enzymes. This 
observation has motivated suggestions that GLGF do- 
mains may regulate enzyme activities or, alternatively, that 
this motif may function as a protein-protein interaction 
domain (Cho et al., 1992b). We find that deletion of the 
GLGF domain of nNOS does not alter NOS catalytic activ- 
ity in transfected cells. On the other hand, we find that 
Sepharose beads linked to a 299 amino acid fusion protein 
containing the GLGF domain in nNOS selectively retain 
dystrophin from skeletal muscle extracts, indicating that 
this domain is capable of interacting with the dystrophin- 
associated complex. The presence of GLGF domains in 
a diverse group of signaling enzymes suggests that some 
of these proteins may also interact with dystrophin com- 
plexes and that the family of dystrophin-associated pro- 
teins may far exceed the structural glycoprotein complex 
that occurs stoichiometrically with dystrophin in skeletal 
muscle. 
The association of nNOS with the dystrophin-glycopro- 
tein complex sheds light on protein interactions involved 
in maintaining the complex. Numerous data establish that 
the cysteine-rich and C-terminal domains of dystrophin 
are necessary and sufficient o establish the glycoprotein 
complex (Ahn and Kunkel, 1995; Campbell, 1995; Suzuki 
et al., 1994). The region(s) of dystrophin that interacts with 
syntrophin remains uncertain. The GLGF domain of syn- 
trophin occurs near the N-terminus of the protein, analo- 
gous to the location of the GLGF domain in nNOS. In vitro 
binding assays show that the C-terminal half of syntro- 
phins interacts with a protein fragment encoded by two 
C-terminal exons of dystrophin, exons 73 and 74 (Ahn 
and Kunkel, 1995; Suzuki et al., 1995; Yang et al., 1995). 
However, an mdx mouse containing a transgene for a trun- 
cated dystrophin protein lacking exons 71-74 fully re- 
stores syntrophins to dystrophin-associated complexes in 
skeletal muscle (Rafael et al., 1994). Together with the 
results of this study, these data suggest that the C-terminal 
half of syntrophins interacts with protein encoded by exons 
73 and 74 of dystrophin and that the GLGF domains of 
syntrophins and nNOS interact with a distinct region of 
dystrophin or perhaps with a distinct protein of the dys- 
trophin complex. 
These results suggest potential roles for nNOS in neuro- 
muscular signaling and disease associated with dys- 
trophin. The dystrophin-associated glycoprotein complex 
has been proposed to mediate neurite-induced clustering 
of acetylcholine receptors via binding of a-dystroglycan 
to agrin (Campanelli et al., 1994; Gee et al., 1994), a neu- 
ron-derived component of the extracellular matrix (Nitkin 
et al., 1987). Association of nNOS (and potentially other 
enzymes containing a GLGF motif [Figure 2]) with dys- 
trophin completes the link between the extracellular matrix 
and intracellular signal-transducing enzymes. NO, which 
modulates synaptic connectivity (Wu et al., 1994) and syn- 
aptic efficacy (Schuman and Madison, 1994) in brain, also 
serves as a retrograde messenger at neuromuscular syn- 
apses and mediates presynaptic suppression, a process 
that prevents polyneuronal innervation of muscle (Wang 
et al., 1995). Targeting of nNOS to dystrophin, which oc- 
curs at extrajunctional sarcolemma, may help eliminate 
formation of extrajunctional synapses (Sealock et al., 
1991). 
Aberrant translocation of nNOS from sarcolemma to 
cytosol in DMD and mdx muscle has implications for 
the pathogenesis of muscular dystrophy. We are cur- 
rently evaluating nNOS distribution in a variety of muscle 
diseases and dystrophies. In preliminary studies we find 
that nNOS occurs normally at the sarcolemma in human 
neurogenic muscle atrophy, central core disease, and se- 
vere childhood autosomal recessive muscular clystrophy 
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(D. S. C., K. A., J. E. B., and D. S. B., unpublished data), 
suggesting specificity of the defect of nNOS in DMD. 
Whereas nNOS accumulates in the muscle cytosol of mdx 
mice, we find that overall nNOS levels in DMD tissue are 
significantly decreased compared with normal human 
muscle. Reasons for this peculiar difference are not clear. 
mdx mice lack skeletal muscle dystrophin, yet display a 
considerably more mild phenotype than human DMD pa- 
tients (Bulfield et al., 1984). It is therefore possible that 
disease progression in DMD causes transcriptional down- 
regulation of nNOS expression. This seems unlikely be- 
cause we find that other animal and human muscle disor- 
ders are not associated with changes in nNOS levels. 
Alternatively, nNOS may be less stable in the cytosol of 
human skeletal muscle and would therefore be more rap- 
idly degraded in DMD. Derangement of NO metabolism 
and reaction of NO with superoxide are responsible for 
tissue damage in certain diseases, including autoimmune 
(Nathan and Xie, 1994) and neurodegenerative processes 
(Dawson et al., 1992; Huang et al., 1994). Free radical 
oxygen intermediates, which occur at high levels in skele- 
tal muscle (Reid et al., 1992a, 1992b), are known to con- 
tribute to cytotoxic damage in various muscle diseases, 
including DMD (Davison et al., 1988). Altered regulation 
of nNOS in dystrophic muscle may augment the toxic inter- 
action of NO and superoxide and contribute to myofiber 
necrosis. Fast-twitch muscle fibers are preferentially af- 
fected in DMD. However, dystrophin and previously identi- 
fied components of the dystrophin-associated complex 
are equally distributed between fast- and slow-twitch fibers 
(Ohlendieck et al., 1991). The selective enrichment of 
nNOS in fast-twitch muscle fibers (Kobzik et al., 1994) 
could help explain the preferential degeneration of this 
fiber type seen in DMD (Webster et al., 1988). Selective 
modulation of skelelal muscle NO levels may offer a novel 
therapeutic modality for DMD. 
Experimental Procedures 
Tissue Extraction and Western Blot Analysis 
Mouse quadriceps keletal muscle was homogenized in 10 vol (w/v) 
of buffer A (25 mM Tris-HCI [pH 7.4], 100 mM NaCI, 1 mM EDTA, 1 
mM EGTA, 1 mM PMSF), and heavy microsomes were prepared by 
a standard protocol with minor modifications (Mitchell et al., 1983). 
Nuclei were pelleted by centrifugation at 1000 x g. The supernatant 
was then centrifuged at 20,000 x g, yielding supernatant S,. The 
resulting heavy microsomal pellet was resuspended in buffer A con- 
taining 500 mM NaCI, incubated for 30 min at 4°C with agitation, and 
centrifuged at 15,000 x g, yielding supernatant $2. This resulting pellet 
was resuspended in buffer Acontaining 500 mM NaCI plus 0.5O/o Triton 
X-100, incubated for 30 rain at 4°C with agitation, and centrifuged at 
15,000 x g, yielding supernatant $3 and a final pellet, P. 
Tissue extracts were resolved by SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) (7.50/o polyacrylamide), and proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes (Immobi- 
Ion-P, Millipore). Membranes were incubated overnight with primary 
antisera (bNOS, 1:250, Transduction Laboratories; eNOS, 1:250, 
Transduction Laboratories; dystrophin, 1:100, Novacastra Labora- 
tories; spectrin, 1:100, Novacastra Laboratories) diluted in Tris-HCI- 
buffered saline containing 3% bovine serum albumin. Immunoreactive 
bands were visualized by enhanced chemiluminescence (ECL) ac- 
cording to the specifications of the manufacturer (Amersham). 
Affinity Chromatography 
For sWGA affinity chromatography, mouse quadriceps from wild-type 
and mdx mice were homogenized and solubilized in 10 vol of buffer 
B (50 mM Tris-HCI [pH 7.4], 200 mM NaCI, 1 mM EDTA, 1 mM PMSF) 
containing 1% digitonin. Solubilized membranes (4 mg)from wild-type 
and mdx mice were circulated for 1 hr with 250 p.I of sWGA-agarose 
(Vector Labs) at 4°C. Columns were washed sequentially with 5 ml 
of buffer B containing 0.1% digitonin, buffer B containing 0.1% digito- 
nin and 500 mM NaCI, and buffer B containing 500 mM NaCI and 
0.5% Triton X-100. Columns were affinity eluted with 1 ml of buffer 
B containing 0.3 M NAG with 0.1% digitonin. Chromatography of rat 
skeletal muscle followed a similar procedure, except 20 mg of solubi- 
lized membranes was loaded onto 1 ml of sWGA that was washed 
with 10 ml of buffers containing 500 mM NaCI and Triton X-100 and 
eluted with 3 ml of 0.3 M NAG. 
For 2',5'-ADP affinity chromatog raphy, mouse quadriceps from wild- 
type and nNOS knockout mice were homogenized in 10 vol (w/v) of 
buffer B, and heavy microsomes were prepared and solubilized in 
buffer B containing 1% digitonin. Solubilized membranes (4 mg) from 
wild-type and nNOS knockout mice were applied to 150 I~1 columns of 
2',5'-ADP-agarose (Sigma). Columns were sequentially washed with 5 
ml of buffer B containing 0.1% digitonin, 1 ml of buffer B containing 
500 mM NaCI and 0.1% digitonin, and 1 ml of buffer B containing 500 
mM NaCI and 0.5% Triton X-100. Columns were affinity eluted with 
1 ml of buffer B containing 20 mM NADPH and 0.1% digitonin. 
GST-Fusion Proteins 
A GST-nNOS(1-299) construct was generated by cloning sequences 
encoding the first 299 amino acids of rat brain NOS into the EcoRI 
site of the pGEX-2T vector. GST-fusion proteins were expressed in 
Escherichia coil and purified on glutathione-Sepharose beads ac- 
cording to the specifications of the manufacturer (Pharmacia; Smith 
and Johnson, 1988). Solubilized skeletal muscle membranes (2 mg) 
were incubated with control (GST) or GST-nNOS(1-299) beads for 1 
hr. Beads were washed with buffer containing 0.5% Triton X-100 plus 
300 mM NaCI, and proteins were eluted with 150 i11 of loading buffer. 
Dystrophin Immunoprecipitation 
Monoclonal antibodies (2 I~g) to dystrephin or Myc epitope (BABCO) 
were added to 1 ml aliquots of NAG eluate (15 p.g), and samples were 
incubated on ice for 1 hr. Rabbit anti-moLrse IgG (10 p.g) (Cappel) was 
then added, and after 30 min, 50 #1 of protein A-Sepharose was used 
to precipitate antibodies. Protein A pellets were washed three times 
with buffer containing 200 mM NaCI and 0.1% Triton X-100. Immune- 
precipitated proteins were denatured with loading buffer and resolved 
by SDS-PAGE. 
Antibodies, Immunohistochemistry, and Immunoblotting 
Unfixed skeletal muscle samples were flash frozen in liquid nitrogen- 
cooled isopentane, sectioned on a cryostat (10 pm), and melted directly 
onto glass slides. Sections were then postfixed in 2% paraformalde- 
hyde-phosphate-buffered saline (PBS). Tissues were blocked in PBS 
containing 1% normal goat serum. Monoclonal antibodies to dys- 
trophin (1:200, Sigma), nNOS (1:100, Transduction Laboratories), 
spectrin (1:50, Novacastra Laboratories), or a polyclonal nNOS anti- 
body (1:250; Kobzik etal., 1994) were applied to sections overnight 
at 4°C. For indirect immunofluorescence, secondary goat anti-rabbit 
fluorescence isothiocyanate (FITC) or donkey anti-mouse Cy-3 conju- 
gated antibodies were used according to the specifications of the man- 
ufacturer (1:200, Jackson Laboratories). 
Mammalian Cell Transfections 
nNOS cDNAs were cloned into the mammalian expression vector 
pcDNA-3 (Invitrogen). Monkey COS cells were grown in culture me- 
dium consisting of DMEM (GIBCO BRL) supplemented with 10% fetal 
bovine serum. Cells were plated in 10 cm dishes at a density of 2 x 
104 per square centimeter and transfected the following day using 
calcium phosphate as previously described (Bredt et al., 1991). Cells 
were washed with PBS 3 days following transfection, harvested in 2 
ml of buffer containing 25 mM Tris-HCI (pH 7.4), 100 mM NaCI, 1 mM 
EDTA, 1 mM EGTA, 1 mM PMSF, and disrupted using a polytron. 
NOS Catalytic Assays 
Quadriceps skeletal muscle from wild-type and mdx mouse were ho- 
mogenized in 10 vol of buffer containing 25 mM Tris-HCI (pH 7.4), 
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1 mM EDTA, 1 mM EGTA, and 0.1 M NaCI. The homogenate was 
centrifuged at 20,000 x g, yielding the soluble fraction. The pellet was 
extracted in the same buffer containing 0.5 M NaCI and centrifuged 
at 20,000 x g, yielding the particulate fraction. Aliquots from these 
fractions were assayed in 125 ~1 reactions containing 100,000 cpm 
of [3H]arginine (60 Ci/mmol), 1 mM NADPH, 400 ~M free calcium, 1 
p.M calmodulin, 3 p,M each of tetrahydrobiopterin, FAD, and FMN. 
After incubation for 25 min at 22°C, assays were terminated with 4 
ml of H20. Samples were applied to 0.5 ml Dowex AG50WX-8 (Na ÷ 
form) columns. [3H]citrulline was quantified by liquid scintillation spec- 
troscopy of the 4 ml flowthrough. Crude homogenates of transfected 
COS cells were assayed using an identical procedure. 
Characterization of Human Tissues 
Human tissues were obtained from the pathology department at Uni- 
versity of California, San Francisco. Clinical diagnosis of DMD was 
made on the basis of onset and progression of disease, the presence of 
creatine kinase in serum, and histologic study of the biopsied muscles. 
Tissues were snap frozen in liquid nitrogen-cooled isopentane. For 
Western blotting, cryostat sections were collected into plastic tubes 
and sonicated in buffer containing 50 mM Tris-HCI (pH 7.4), 1 mM 
EDTA, 1 mM EGTA, and 1 mM PMSF. Crude protein samples (200 
I~g per lane) were resolved by SDS-PAGE and analyzed by Western 
blotting as described above. Immunohistochemistry was performed 
on 10 I~m human tissue samples as described above. To ensure speci- 
ficity, we performed immunofluorescent NOS staining using two inde- 
pendently raised antisera. The first antiserum (~-nNOS1) reacts only 
with determinants in the N-terminal domain of nNOS (Bredt and Sny- 
der, 1994b), while the second (cc-nNOS2) reacts only with the C-ter- 
minal region (Transduction Laboratories). Unless otherwise noted, all 
histologic sections were labeled with (~-nNOSI. 
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